-
-
Approval By The U.S. Fda For Clinical Trial Of The Mrna Herpes Zoster Vaccine Its Humoral And Cellular Immunity Was Significantly Higher Than Those Of Internationally Commercially Available Recombinant Subunit Vaccines
2025-03-24The clinical trial approval for the mRNA herpes zoster vaccine has been recently received from the U.S. Food and Drug Administration (“FDA”). This is the second innovative vaccine product of the Group approved by the U.S. FDA for clinical trials, following the mRNA RSV vaccine, which marks a new milestone in the Group’s globalization strategy.
-
-
Significant Decrease In Loss Of The Company’S Results
2025-03-18The Group is expected to record an unaudited revenue ranging from RMB1.25 billion to RMB1.3 billion for the Reporting Period, representing an increase ranging from RMB60 million to RMB110 million or 5% to 9% as compared to the revenue of RMB1.19 billion for the previous year; and the Group is expected to record an unaudited net loss ranging from RMB250 million to RMB290 million, representing a significant decrease in loss ranging from RMB1.66 billion to RMB1.7 billion or 85% to 87% as compared to the net loss of RMB1.95 billion in the previous year.
-
-
Aimei Vaccines Assists in the Successful Holding of the 2023 Northeast Three Provinces Vaccine Preventable Disease Prevention and Control Experience Exchange Meeting
2023-04-04 -
The 2023 Northeast Three Provinces Vaccine Preventable Disease Prevention and Control Experience Exchange Meeting, organized by the Liaoning Provincial Society of Preventive Medicine, co-organized by Aimei Vaccines Co., Ltd. and Yunnan Watson Biotechnology Co., Ltd., and hosted by Dalian Jiuyi Biomedical Technology Co., Ltd., was successfully held in Dalian. The meeting focused on the exchange of experiences in the prevention and control of diseases such as hepatitis B, rabies, and cervical cancer. Aimei Vaccines' hepatitis B vaccine produced by Aimei Chengxin and Ningbo Rong'an, as well as the human rabies vaccine, received full recognition from the attending experts.
-
-
-
Subjects was Grouped for Clinical Test on the Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Another Key Product of AIM Vaccine
2023-03-17 -
Another key product — quadrivalent meningococcal conjugate vaccine (MCV4) has been developed independently by AIM Vaccine. On March 15, the clinical test was officially carried out at Yanshan Disease Prevention and Control Center in Yunnan Province and related subjects were grouped.
-
-
-
Bivalent Delta Omicron BA.5 mRNA COVID-19 Vaccine was Approved for Phase-III Clinical Test in Pakistan
2023-03-14 -
Recently, AIM Vaccine’s bivalent Delta+ Omicron BA.5 mRNA COVID-19 vaccine under development was officially approved for Phase-III clinical test in Pakistan. The results of two clinical researches previously conducted in China indicate good safety, and the results of tests on live virus and antibody show that such vaccine under development can induce high-level neutralizing antibody against Delta, Omicron BA.5, BQ.1, and XBB variants of COVID-19 virus.
-
-
-
Expanded Shanghai-Hong Kong Connect Stocks and the Notice Will Take Effect from Next Monday
2023-03-06 -
In the Notice on the First Adjustment of Hong Kong Stock Connect Targets after the Expansion of Shanghai-Hong Kong Connect Targets recently released by Shanghai Stock Exchange, AIM VACCINE (06660.HK) was incorporated into the first group of newly expanded Hong Kong Connect stocks under Shanghai-Hong Kong Connect Business. The Notice will take effect from March 13, 2023 (next Monday).
-
-
-
Two Types of mRNA COVID-19 Vaccines Produced by AIM Vaccine was Approved for Clinical Test in Pakistan
2023-02-15 -
On February 13, 2023, the candidate mRNA vaccine for COVID-19 virus variant strain produced by AIM Vaccine was officially approved for Phase-I clinical test in Pakistan. On the same day, the candidate mRNA vaccine for COVID-19 prime strain produced by our group was officially approved for Phase-III clinical test for sequential booster shot in Pakistan.
-
-
-
Rongan Biological was Selected on the List of Specialized, Refined, Differentiated and Innovative “Little Giant” Key Incubation Enterprises in Ningbo in 2023
2023-02-15 -
A few days ago, Ningbo Municipal Bureau of Economy and Information Technology issued an announcement that 650 enterprises were determined as specialized, refined, differentiated and innovative “Little Giant” key incubation enterprises in Ningbo in 2023, including Ningbo Rongan Biomedicine Co., Ltd. subordinate to AIM Vaccine.
-
-
-
AIM Vaccine Joins Hands with Fortune Global 500 Enterprises to Create the Global Industrial Highland for “Intelligent Manufacturing of New Medicine” in Beijing Economic-Technological Development Area
2023-02-15 -
On the morning of February 14, Beijing Economic-Technological Development Area held the Global Partner Conference on “Intelligent Manufacturing of New Medicine” and declared that it would accelerate the construction of a global industrial highland for “intelligent manufacturing of new medicine”. AIM Vaccine, together with a group of Fortune Global 500 enterprises such as Bayer, Sanofi, GE Healthcare, and Varian, as well as domestic leading bio-medical enterprises, attended the signing ceremony at the conference.
-
